- Home
- DXCM vs A Comparison
DXCM vs A Comparison
Compare DXCM & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXCM
- A
- Stock Information
- Founded
- DXCM 1999
- A 1999
- Country
- DXCM United States
- A United States
- Employees
- DXCM N/A
- A N/A
- Industry
- DXCM Medical/Dental Instruments
- A Biotechnology: Laboratory Analytical Instruments
- Sector
- DXCM Health Care
- A Industrials
- Exchange
- DXCM Nasdaq
- A Nasdaq
- Market Cap
- DXCM 31.7B
- A 34.9B
- IPO Year
- DXCM 2005
- A 1999
- Fundamental
- Price
- DXCM $65.96
- A $138.75
- Analyst Decision
- DXCM Strong Buy
- A Buy
- Analyst Count
- DXCM 19
- A 9
- Target Price
- DXCM $97.42
- A $142.22
- AVG Volume (30 Days)
- DXCM 6.7M
- A 1.8M
- Earning Date
- DXCM 10-30-2025
- A 11-24-2025
- Dividend Yield
- DXCM N/A
- A 0.72%
- EPS Growth
- DXCM N/A
- A N/A
- EPS
- DXCM 1.43
- A 4.28
- Revenue
- DXCM $4,300,800,000.00
- A $6,788,000,000.00
- Revenue This Year
- DXCM $17.01
- A $8.36
- Revenue Next Year
- DXCM $15.36
- A $5.49
- P/E Ratio
- DXCM $46.17
- A $32.34
- Revenue Growth
- DXCM 9.30
- A 4.48
- 52 Week Low
- DXCM $57.52
- A $96.43
- 52 Week High
- DXCM $93.25
- A $153.84
- Technical
- Relative Strength Index (RSI)
- DXCM 32.71
- A 69.03
- Support Level
- DXCM $63.53
- A $120.78
- Resistance Level
- DXCM $68.00
- A $143.09
- Average True Range (ATR)
- DXCM 2.97
- A 3.26
- MACD
- DXCM -0.10
- A 1.50
- Stochastic Oscillator
- DXCM 19.63
- A 83.10
About DXCM DexCom Inc.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About A Agilent Technologies Inc.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.